Developer docs
API playgroundTry for free, no card

Search company profiles

Health Advances

Full company profile

uuid0006k2e

Namestring
Health Advances
Legal namestring
Health Advances LLC
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Health Advances is a privately held, healthcare- and life-sciences-focused boutique strategy consulting firm founded around 1996 (firmographics note 1992) and headquartered at 275 Grove Street in Newton, Massachusetts. The firm was co-founded by Paula Ness Speers and Mark Speers, who continue as Senior Advisors, and is led operationally by a Managing Partner and Global Head (Sheela Hegde) alongside Practice Heads for Biopharma (Vivek Mittal, PhD), MedTech, Digital Health and HIT (Susan A. Posner), Commercial and Growth (Greg Chittem), and Diagnostics, Precision Medicine and Life Science Tools (Donna Hochberg, PhD). Health Advances operates through wholly-owned subsidiaries in San Francisco, Zug, Switzerland (Health Advances GmBH), and Hong Kong (Health Advances Asia Limited), and reports engagement activity across 80 countries.

The firm offers six core consulting capabilities — Corporate Strategy, Product Development & Portfolio Strategy, Go-to-Market & Commercial Strategy, Business Development Strategy, Commercial Diligence, and Market Access & Pricing — delivered across five sectors (Biotech & Pharmaceuticals, Diagnostics/Precision Medicine/Life Science Tools, MedTech, Digital Health & Enterprise HIT, and Investors) and 14+ therapeutic-area practices including Cell & Gene Therapy, Oncology, CNS, Cardiovascular, Diabetes & Metabolics, and Rare Diseases. Service delivery relies on human capital (staff with MD, PhD, and PharmD credentials), proprietary sector-specific databases and expert networks, and a formal strategic alliance with CRO Parexel that provides client access to ex-FDA/EMEA clinical and regulatory advisors.

Health Advances generates revenue through professional-services engagements on a project-by-project basis; pricing is not publicly disclosed and is negotiated by scope, team composition, and requirements. Customers span 1,000+ companies and investors (from early-stage biotech to large pharma, plus private equity and venture capital), served via a sales-led motion through direct consulting engagements. Cumulative scale includes 3,500+ assignments completed and consistent Vault #1 rankings for Formal Training. The firm has no disclosed outside equity, no acquisitions, and no public revenue figures; operations are organic, partner-led, and global.

Short descriptiontext

Health Advances is a privately held, healthcare- and life-sciences-only boutique strategy consulting firm serving biotech, pharma, MedTech, diagnostics, digital health companies, and healthcare investors across 80 countries from offices in Newton, San Francisco, Zug, and Hong Kong.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNewton, United States
HQ citystring
Newton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare consulting, life sciences advisory, strategic consulting, commercial diligence, biopharma advisory
Industry2 codes
PRIMARYBPACADAK
Healthcare IT & Health Informatics Staffing
Business & Public Services/HR, Staffing & Recruitment Services/Professional & Technical Staffing (IT/Engineering/Healthcare/Finance)
SECONDARYBPACAAAE
Healthcare & Life Sciences Leadership Search
NAICS code2 codes
  • Human Resources Consulting Services541612
  • Management Consulting Services54161
SIC code2 codes
  • Services-Management Consulting Services8742
  • Services-Misc Health & Allied Services, Nec8090
Product category
Healthcare and Life Sciences Consulting
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Strategic Consulting Services
TypeProfessional Services
Description

Health Advances generates revenue through providing strategic consulting services to healthcare and life sciences companies. They offer corporate strategy, product development, go-to-market, business development, and commercial diligence services. The firm works with early-stage startups to large pharmaceutical companies, serving as trusted advisors on strategic questions.

healthadvances.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Health Advances is a boutique healthcare and life sciences consulting firm that delivers strategic advisory services to biopharmaceutical, diagnostics, MedTech, and digital health companies, as well as healthcare investors. Its core offerings span five consulting capabilities: corporate strategy, product development and portfolio strategy, go-to-market and commercial strategy, business development strategy, and commercial diligence. The firm has supported over 1,000 companies and investors across 3,500+ assignments, organized across sector and therapeutic practice areas with deep domain expertise and proprietary databases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Worked with over 1,000 companies and investors on over 3,500 assignments
+2 more records
Product overview1 text field

Health Advances is a healthcare and life sciences consulting firm offering strategic advisory services across five core consulting engagements: Corporate Strategy, Product Development & Portfolio Strategy, Go-to-Market & Commercial Strategy, Business Development Strategy, and Commercial Diligence. The firm works with over 1,000 companies and investors on over 3,500 assignments. These services are organized by sector expertise (Biotech & Pharmaceuticals, Diagnostics Precision Medicine & Life Science Tools, MedTech, Digital Health & Enterprise HIT, and Investors) and therapeutic practices (Allergy & Immunology, Bioprocessing, Cardiovascular, Cell & Gene Therapy, CNS Diseases, Contract Pharma Services, Diabetes & Metabolics, Digital Therapeutics, Drug Delivery Devices, Life Science Tools & Services, Oncology, Precision Medicine, Rare Diseases, Real-World Data & Analytics, Women's Health). The consulting engagements are delivered through practice-specific teams with deep expertise, proprietary databases, and networks of external experts.

Product and service6 records
1Corporate Strategy
CategoryStrategic Consulting
Description

Strategic advisory service focused on making hard choices that give healthcare and life sciences companies the focus necessary to achieve sustainable competitive advantage.

2Product Development & Portfolio Strategy
CategoryStrategic Consulting
Description

Consulting service focused on thoughtful prioritization and sharp strategy to translate innovation into commercial value, including clinical development paths, target product profiles, and portfolio optimization.

3Go-to-Market & Commercial Strategy
CategoryStrategic Consulting
Description

Strategic advisory on stakeholder buying processes, reimbursement, business models, ideal customer profiles, and global commercialization strategies for new health technologies.

4Business Development Strategy
CategoryStrategic Consulting
Description

Advisory service to prioritize growth opportunities that leverage right-to-win, strategic fit, and optimize portfolio value.

5Commercial Diligence
CategoryStrategic Consulting
Description

Data-driven, rigorously quantified assessments to gain realistic pictures of opportunities, spot synergies, and prepare for deal-making, including buy-side and sell-side due diligence for investors and corporate acquirers.

6Market Access & Pricing
CategoryStrategic Consulting
Description

Advisory on integrating value and access considerations early and throughout trials and product lifecycle to maximize commercial potential, including evidence generation, cost containment measures, HTA pathways, and reimbursement strategies.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Health Advances has a formal relationship with Parexel, a leading CRO. Parexel colleagues include medical directors who have designed and executed clinical trials across virtually every therapeutic area, and regulatory experts who provide practical advice from their years at FDA, EMEA and other global authorities. This collaboration enhances Health Advances' ability to offer comprehensive strategic advisory services spanning clinical development and regulatory strategy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Life sciences commercial strategy and insights firm serving biopharma clients across portfolio strategy, launch, and market access. Direct peer: comparable boutique-to-mid-size scale, overlapping therapeutic-area depth, and expanding investment in proprietary data and analytics assets.

TypeBroad incumbent
Description

Global strategy consultancy with a strong healthcare and life sciences practice serving biopharma, MedTech, and PE healthcare investors. Broad incumbent: directly competes on commercial diligence and corporate strategy engagements, particularly for PE/VC healthcare clients.

3ZS Associates
TypeDirect peer
Description

Global consulting firm focused on healthcare and related industries, with deep biopharma commercial and sales/marketing expertise. Direct peer: serves the same pharma/biotech buyer base with overlapping go-to-market, commercial strategy, and launch advisory offerings.

TypeDirect peer
Description

Global consultancy with a major Healthcare & Life Sciences practice, particularly strong in pricing, market access, and commercial strategy. Direct peer where engagements overlap on market access, pricing, and go-to-market work for biopharma clients.

TypeDirect peer
Description

Global consulting firm with a Life Sciences practice offering strategic and economic advisory services to pharma, biotech, and MedTech clients. Direct peer on commercial strategy, pricing/market access, and life sciences due diligence mandates.

TypeDirect peer
Description

Boutique strategy consulting firm focused exclusively on the life sciences industry, covering corporate strategy, therapeutic area strategy, and commercial diligence. Direct peer by both business model (boutique, healthcare-only) and service offerings; primary competition in commercial diligence work for PE/VC clients.

TypeDirect peer
Description

Boutique life sciences strategy consulting firm specializing in biopharma commercial strategy, portfolio prioritization, and launch planning. Direct peer by both scale and service mix — comparable boutique model serving similar biotech/pharma strategy and commercial diligence needs.

TypeDirect peer
Description

Global strategy consultancy with one of the largest dedicated healthcare and life sciences practices. Closest direct competitor: similar boutique-to-mid-size positioning, comparable client mix across pharma/biotech/MedTech, and overlapping service lines in corporate strategy, commercial diligence, and product portfolio strategy.

TypeBroad incumbent
Description

Global management consultancy with one of the largest healthcare practices covering biopharma, MedTech, and healthcare systems. Broad incumbent: competes on the same corporate strategy, portfolio, and commercial diligence mandates but with vastly larger bench and broader industry portfolio.

TypeBroad incumbent
Description

Global strategy consultancy with a major healthcare practice serving pharma, biotech, MedTech, and providers. Broad incumbent: overlapping corporate strategy and portfolio advisory work, with much greater scale and integrated delivery capability.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Health Advances

Healthcare and Life Sciences Consultinghealthadvances.com

Health Advances is a privately held, healthcare- and life-sciences-only boutique strategy consulting firm serving biotech, pharma, MedTech, diagnostics, digital health companies, and healthcare investors across 80 countries from offices in Newton, San Francisco, Zug, and Hong Kong.

What Health Advances does

Health Advances is a privately held, healthcare- and life-sciences-focused boutique strategy consulting firm founded around 1996 (firmographics note 1992) and headquartered at 275 Grove Street in Newton, Massachusetts. The firm was co-founded by Paula Ness Speers and Mark Speers, who continue as Senior Advisors, and is led operationally by a Managing Partner and Global Head (Sheela Hegde) alongside Practice Heads for Biopharma (Vivek Mittal, PhD), MedTech, Digital Health and HIT (Susan A. Posner), Commercial and Growth (Greg Chittem), and Diagnostics, Precision Medicine and Life Science Tools (Donna Hochberg, PhD). Health Advances operates through wholly-owned subsidiaries in San Francisco, Zug, Switzerland (Health Advances GmBH), and Hong Kong (Health Advances Asia Limited), and reports engagement activity across 80 countries.

The firm offers six core consulting capabilities — Corporate Strategy, Product Development & Portfolio Strategy, Go-to-Market & Commercial Strategy, Business Development Strategy, Commercial Diligence, and Market Access & Pricing — delivered across five sectors (Biotech & Pharmaceuticals, Diagnostics/Precision Medicine/Life Science Tools, MedTech, Digital Health & Enterprise HIT, and Investors) and 14+ therapeutic-area practices including Cell & Gene Therapy, Oncology, CNS, Cardiovascular, Diabetes & Metabolics, and Rare Diseases. Service delivery relies on human capital (staff with MD, PhD, and PharmD credentials), proprietary sector-specific databases and expert networks, and a formal strategic alliance with CRO Parexel that provides client access to ex-FDA/EMEA clinical and regulatory advisors.

Health Advances generates revenue through professional-services engagements on a project-by-project basis; pricing is not publicly disclosed and is negotiated by scope, team composition, and requirements. Customers span 1,000+ companies and investors (from early-stage biotech to large pharma, plus private equity and venture capital), served via a sales-led motion through direct consulting engagements. Cumulative scale includes 3,500+ assignments completed and consistent Vault #1 rankings for Formal Training. The firm has no disclosed outside equity, no acquisitions, and no public revenue figures; operations are organic, partner-led, and global.

Health Advances firmographics

Firmographics
Name
Health Advances
Legal name
Health Advances LLC
Website
https://healthadvances.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
101–250 employees
Short description
Health Advances is a privately held, healthcare- and life-sciences-only boutique strategy consulting firm serving biotech, pharma, MedTech, diagnostics, digital health companies, and healthcare investors across 80 countries from offices in Newton, San Francisco, Zug, and Hong Kong.
Ownership category
akta.pro rank

Health Advances industry classification

Industry
Product category
Healthcare and Life Sciences Consulting
NAICS
Human Resources Consulting Services (541612), Management Consulting Services (54161)
SIC
Services-Management Consulting Services (8742), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYBPACADAK
Healthcare IT & Health Informatics Staffing
Business & Public Services/HR, Staffing & Recruitment Services/Professional & Technical Staffing (IT/Engineering/Healthcare/Finance)
SECONDARYBPACAAAE
Healthcare & Life Sciences Leadership Search

Keywords

  • Healthcare consulting
  • Life sciences advisory
  • Strategic consulting
  • Commercial diligence
  • Biopharma advisory

Where Health Advances is headquartered

Location

Headquarters

HQ city
Newton
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Health Advances business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Strategic Consulting Services: Health Advances generates revenue through providing strategic consulting services to healthcare and life sciences companies. They offer corporate strategy, product development, go-to-market, business development, and commercial diligence services. The firm works with early-stage startups to large pharmaceutical companies, serving as trusted advisors on strategic questions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Health Advances product offering

Product offering

Core offering

Health Advances is a boutique healthcare and life sciences consulting firm that delivers strategic advisory services to biopharmaceutical, diagnostics, MedTech, and digital health companies, as well as healthcare investors. Its core offerings span five consulting capabilities: corporate strategy, product development and portfolio strategy, go-to-market and commercial strategy, business development strategy, and commercial diligence. The firm has supported over 1,000 companies and investors across 3,500+ assignments, organized across sector and therapeutic practice areas with deep domain expertise and proprietary databases.

Product overview

Health Advances is a healthcare and life sciences consulting firm offering strategic advisory services across five core consulting engagements: Corporate Strategy, Product Development & Portfolio Strategy, Go-to-Market & Commercial Strategy, Business Development Strategy, and Commercial Diligence. The firm works with over 1,000 companies and investors on over 3,500 assignments. These services are organized by sector expertise (Biotech & Pharmaceuticals, Diagnostics Precision Medicine & Life Science Tools, MedTech, Digital Health & Enterprise HIT, and Investors) and therapeutic practices (Allergy & Immunology, Bioprocessing, Cardiovascular, Cell & Gene Therapy, CNS Diseases, Contract Pharma Services, Diabetes & Metabolics, Digital Therapeutics, Drug Delivery Devices, Life Science Tools & Services, Oncology, Precision Medicine, Rare Diseases, Real-World Data & Analytics, Women's Health). The consulting engagements are delivered through practice-specific teams with deep expertise, proprietary databases, and networks of external experts.

Differentiator

Problem solved

Functional benefit

Products and services

  • Corporate Strategy Strategic advisory service focused on making hard choices that give healthcare and life sciences companies the focus necessary to achieve sustainable competitive advantage.
  • Product Development & Portfolio Strategy Consulting service focused on thoughtful prioritization and sharp strategy to translate innovation into commercial value, including clinical development paths, target product profiles, and portfolio optimization.
  • Go-to-Market & Commercial Strategy Strategic advisory on stakeholder buying processes, reimbursement, business models, ideal customer profiles, and global commercialization strategies for new health technologies.
  • Business Development Strategy Advisory service to prioritize growth opportunities that leverage right-to-win, strategic fit, and optimize portfolio value.
  • Commercial Diligence Data-driven, rigorously quantified assessments to gain realistic pictures of opportunities, spot synergies, and prepare for deal-making, including buy-side and sell-side due diligence for investors and corporate acquirers.
  • Market Access & Pricing Advisory on integrating value and access considerations early and throughout trials and product lifecycle to maximize commercial potential, including evidence generation, cost containment measures, HTA pathways, and reimbursement strategies.

Quantifiable outcome

  • Worked with over 1,000 companies and investors on over 3,500 assignments
  • +2 more outcomes

Companies that use Health Advances

Customer profile

Named customers2 records

Segments5 records

Ideal customer profiles5 records

Health Advances technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Health Advances partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ParexelcoreStrategic or Co-development PartnerHealth Advances has a formal relationship with Parexel, a leading CRO. Parexel colleagues include medical directors who have designed and executed clinical trials across virtually every therapeutic area, and regulatory experts who provide practical advice from their years at FDA, EMEA and other global authorities. This collaboration enhances Health Advances' ability to offer comprehensive strategic advisory services spanning clinical development and regulatory strategy.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Health Advances competitors and assessment

Company assessment

Direct peers

  • Trinity Life Sciences: Life sciences commercial strategy and insights firm serving biopharma clients across portfolio strategy, launch, and market access. Direct peer: comparable boutique-to-mid-size scale, overlapping therapeutic-area depth, and expanding investment in proprietary data and analytics assets.
  • ZS Associates: Global consulting firm focused on healthcare and related industries, with deep biopharma commercial and sales/marketing expertise. Direct peer: serves the same pharma/biotech buyer base with overlapping go-to-market, commercial strategy, and launch advisory offerings.
  • Simon-Kucher & Partners: Global consultancy with a major Healthcare & Life Sciences practice, particularly strong in pricing, market access, and commercial strategy. Direct peer where engagements overlap on market access, pricing, and go-to-market work for biopharma clients.
  • Charles River Associates: Global consulting firm with a Life Sciences practice offering strategic and economic advisory services to pharma, biotech, and MedTech clients. Direct peer on commercial strategy, pricing/market access, and life sciences due diligence mandates.
  • ClearView Healthcare Partners: Boutique strategy consulting firm focused exclusively on the life sciences industry, covering corporate strategy, therapeutic area strategy, and commercial diligence. Direct peer by both business model (boutique, healthcare-only) and service offerings; primary competition in commercial diligence work for PE/VC clients.
  • Putnam Associates: Boutique life sciences strategy consulting firm specializing in biopharma commercial strategy, portfolio prioritization, and launch planning. Direct peer by both scale and service mix — comparable boutique model serving similar biotech/pharma strategy and commercial diligence needs.
  • LEK Consulting: Global strategy consultancy with one of the largest dedicated healthcare and life sciences practices. Closest direct competitor: similar boutique-to-mid-size positioning, comparable client mix across pharma/biotech/MedTech, and overlapping service lines in corporate strategy, commercial diligence, and product portfolio strategy.

Broad incumbents

  • Bain & Company (Healthcare Practice): Global strategy consultancy with a strong healthcare and life sciences practice serving biopharma, MedTech, and PE healthcare investors. Broad incumbent: directly competes on commercial diligence and corporate strategy engagements, particularly for PE/VC healthcare clients.
  • McKinsey & Company (Pharma & Medical Products Practice): Global management consultancy with one of the largest healthcare practices covering biopharma, MedTech, and healthcare systems. Broad incumbent: competes on the same corporate strategy, portfolio, and commercial diligence mandates but with vastly larger bench and broader industry portfolio.
  • Boston Consulting Group (Healthcare Practice): Global strategy consultancy with a major healthcare practice serving pharma, biotech, MedTech, and providers. Broad incumbent: overlapping corporate strategy and portfolio advisory work, with much greater scale and integrated delivery capability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Health Advances social profiles

Digital presence

Health Advances financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Health Advances leadership team

Management profile

Number of profiles

Profiles20 records

Health Advances subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Health Advances funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Health Advances M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Health Advances

What does Health Advances do?

Health Advances is a boutique healthcare and life sciences consulting firm that delivers strategic advisory services to biopharmaceutical, diagnostics, MedTech, and digital health companies, as well as healthcare investors. Its core offerings span five consulting capabilities: corporate strategy, product development and portfolio strategy, go-to-market and commercial strategy, business development strategy, and commercial diligence. The firm has supported over 1,000 companies and investors across 3,500+ assignments, organized across sector and therapeutic practice areas with deep domain expertise and proprietary databases.

Is Health Advances a public or private company?

Health Advances is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Health Advances founded?

Health Advances was founded in 1996. It employs 101 to 250 people.

Where is Health Advances based?

Health Advances is headquartered in Newton, United States, in the North America region.

How does Health Advances make money?

One revenue line is on record: strategic Consulting Services.

Who are Health Advances's main competitors?

Direct peers on record are Trinity Life Sciences, ZS Associates, Simon-Kucher & Partners, Charles River Associates, ClearView Healthcare Partners, Putnam Associates and LEK Consulting. Broad incumbents are Bain & Company (Healthcare Practice), McKinsey & Company (Pharma & Medical Products Practice) and Boston Consulting Group (Healthcare Practice).

Does Health Advances have an API?

No public API is recorded for Health Advances.

What industry is Health Advances in?

Health Advances's product category is Healthcare and Life Sciences Consulting. Its primary akta.pro industry code is BPACADAK, Healthcare IT & Health Informatics Staffing, with a secondary code of BPACAAAE, Healthcare & Life Sciences Leadership Search. Its NAICS code is 541612 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HealthadvancesHealth Advances Insights :: Health AdvancesHealth Advances and Parexel published an analysis on the strategic integration of digital biomarkers into neuroscience clinical trials to improve data objectivity and trial efficiency. The authors outline three key strategies for pharmaceutical sponsors: leveraging technologies where they add the most value, selecting partners based on validation maturity, and planning for commercial deployment realities. This approach aims to help sponsors mitigate regulatory risks while achieving a positive return on investment through faster adaptive decisions and reduced trial burdens.ParexelThe Rise of Digital Biomarkers and MeasuresThe article outlines strategies for pharmaceutical sponsors to effectively integrate digital biomarkers into clinical trials to improve efficiency and reduce costs while managing regulatory risks. It highlights the importance of selecting validated technologies that offer high value in development phases and carefully planning for commercial deployment realities such as payer reimbursement and physician adoption. Parexel and Health Advances are presented as key advisors helping companies navigate these complex strategic decisions to achieve positive ROI.HealthadvancesHealth Advances Insights :: Health AdvancesHealth Advances published an analysis outlining a four-stage evolutionary framework for the adoption of artificial intelligence in bioprocessing, ranging from current data analysis support to future autonomous workflows. The report identifies key industry players such as Apprentice, Aizon, DataHow, New Wave Biotech, and BioRaptor that are currently providing or developing these AI-driven solutions.ParexelFocusing on value drivers to reduce risk in early-stage drug development :: ConcreteParexel and Health Advances published a guide for biotech startups on reducing risk in early-stage drug development by focusing on value drivers to secure investment. The article advises companies to prioritize product differentiation, manage competitive risks, and utilize tools like artificial intelligence to generate evidence efficiently.HealthadvancesHealth Advances Insights :: Health AdvancesHealth Advances published an industry outlook analysis on the US gene therapy market for 2024 and beyond, noting that while FDA approvals accelerated to five gene therapies in 2023 (including the first CRISPR-based therapy) with potentially five more expected in 2024, the sector continues to face investor hesitation, commercial underperformance, and manufacturing challenges. The report features bluebird bio as a case study—despite having three FDA-approved products, the company trades at under $200 million market cap due to pricing disputes in Europe, a $3.1 million list price for Lyfgenia that exceeded ICER benchmarks, and a black box safety warning—while competing directly against Vertex and CRISPR Therapeutics' Casgevy at $2.2 million. The analysis suggests the sector's next phase of growth will depend on commercial success metrics from sickle cell disease therapies, new indications expanding addressable populations, and FDA support programs like the CoGenT Global pilot.GlobeNewswireDigital therapeutics executive Jeffrey Abraham joins Health Advances, bolstering the firm’s industry-leading digital health practiceHealth Advances appointed Jeffrey Abraham as Vice President and Co-Leader of its Digital Health and Health IT Practice. Abraham brings experience from Akili Interactive and prior roles at The Medicines Company and Gfk. His addition bolsters the firm's digital therapeutics capabilities.The GuardianWill having longer, healthier lives be worth losing the most basic kinds of privacy? | John HarrisGoogle is acquiring Fitbit for $2.1bn, advancing its healthcare push. The article warns that companies like Google and Amazon access NHS and US medical data, raising privacy concerns. It notes regulators have not yet approved the deal and calls for new rules.Business Wire BlogParexel Extends Asia/Pacific Capability with the Launch of Health Advances Asia LimitedParexel announced the launch of Health Advances Asia Limited in Hong Kong to support drug development and commercialization in Asia/Pacific. The team will be led by Gary Cheng, with Vivek Mittal also based in Hong Kong. Parexel now has eight offices and over 1,700 employees in Greater China.